WEBULL

What Bristol-Myers Squibb (BMY)'s Oncology Milestones and Steady Dividend Mean For Shareholders

Simply Wall St · 2d ago
  • Bristol Myers Squibb recently reported a series of oncology milestones, including FDA priority review for Opdivo plus AVD in advanced classical Hodgkin lymphoma and U.S. approval of Breyanzi for relapsed or refractory marginal zone lymphoma, alongside new hematology data at the ASH Annual Meeting.
  • At the same time, the company extended its 94-year dividend record with a US$0.63 quarterly common dividend and secured new antibody-discovery collaborations, underscoring how late-stage innovation, cash returns, and external partnerships are shaping its long-term profile in cancer care.
  • We’ll now examine how Opdivo’s priority review in advanced Hodgkin lymphoma could influence Bristol Myers Squibb’s broader investment narrative and risk profile.

AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol Myers Squibb, you really need to believe that its oncology pipeline can offset looming patent cliffs on blockbusters like Eliquis and, eventually, Opdivo. The Opdivo priority review in advanced Hodgkin lymphoma is an important near term catalyst but does not change the central risk that generic and biosimilar competition could pressure revenue once exclusivities fade.

Among the recent updates, the FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma looks especially relevant. It extends BMS’s cell therapy footprint in lymphomas, adding another approved oncology asset alongside Opdivo at a time when investors are focused on whether newer therapies, including CAR T, CELMoDs and protein degraders, can meaningfully replenish revenue as existing products face competition.

Yet behind the new approvals and pipeline headlines, investors should also be aware that looming patent expiries could...

Read the full narrative on Bristol-Myers Squibb (it's free!)

Bristol-Myers Squibb's narrative projects $41.3 billion revenue and $9.2 billion earnings by 2028. This implies revenues declining by 4.7% per year and an earnings increase of about $4.2 billion from $5.0 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $53.55 fair value, in line with its current price.

Exploring Other Perspectives

BMY 1-Year Stock Price Chart
BMY 1-Year Stock Price Chart

Eleven members of the Simply Wall St Community see Bristol Myers Squibb’s fair value anywhere between US$50 and about US$118, underlining how far apart individual views can be. When you set those opinions against the central risk of major upcoming patent cliffs on drugs like Eliquis and Opdivo, it becomes even more important to compare several perspectives before deciding how resilient you think the business will be.

Explore 11 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 7% less than the current price!

Build Your Own Bristol-Myers Squibb Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.